Inhibrx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	153.09	152.6	277.92	-	131.3
Cash & Short-Term Investments	153.09	152.6	277.92	-	131.3
Cash Growth	-22.03%	-45.09%	-	-	-
Accounts Receivable	0.11	0.4	0.78	0.24	-
Other Receivables	0.73	0.02	-	0.01	-
Receivables	0.84	0.42	0.78	0.26	-
Inventory	2.25	2	9.89	0.81	-
Prepaid Expenses	3.55	4.19	5.67	4.53	-
Other Current Assets	1.7	1.2	1.09	0.67	7.81
Total Current Assets	161.42	160.4	295.36	6.26	139.11
Property, Plant & Equipment	10.31	13.54	9.37	7.22	-
Other Long-Term Assets	5.74	6.83	3.16	3.16	11.34
Total Assets	177.47	180.77	307.89	16.65	150.45
Accounts Payable	12.69	14.89	33.76	9.45	-
Accrued Expenses	21.05	24.25	20.49	9.46	-
Current Portion of Leases	2.25	1.6	2.06	1.86	-
Other Current Liabilities	-	-	-	-	22.45
Total Current Liabilities	35.98	40.73	56.31	20.77	22.45
Long-Term Debt	99.92	-	206.97	-	70.47
Long-Term Leases	4.74	6.45	1.11	3.17	-
Other Long-Term Liabilities	-	-	-	-	5.14
Total Liabilities	140.64	47.18	264.39	23.95	98.07
Common Stock	0	0	0.01	-7.3	52.38
Additional Paid-In Capital	250.18	239.72	657.23	-	-
Retained Earnings	-213.35	-106.13	-613.73	-	-
Shareholders' Equity	36.83	133.58	43.5	-7.3	52.38
Total Liabilities & Equity	177.47	180.77	307.89	16.65	150.45
Total Debt	106.91	8.05	210.14	5.03	70.47
Net Cash (Debt)	46.18	144.55	67.78	-5.03	60.83
Net Cash Growth	-76.25%	113.25%	-	-	-
Net Cash Per Share	2.98	9.65	5.75	-0.13	1.60
Filing Date Shares Outstanding	14.54	14.48	11.78	40.11	38.58
Total Common Shares Outstanding	14.5	14.48	11.78	40.11	38.58
Working Capital	125.44	119.67	239.05	-14.51	116.66
Book Value Per Share	2.54	9.23	3.69	-0.18	1.36
Tangible Book Value	36.83	133.58	43.5	-7.3	52.38
Tangible Book Value Per Share	2.54	9.23	3.69	-0.18	1.36
Machinery	10.1	10.31	9.02	7.55	-
Construction In Progress	-	-	3.59	-	-
Leasehold Improvements	0.8	0.8	0.44	0.44	-

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q